EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Role of FGFR3 in the Progression of Bladder Cancer

Sahoko Ninomiya, Yukari Ishiguro, Hisashi Hasumi iD, Ryosuke Jikuya, Akihito Hashizume iD, Masanobu Yamazaki, Jun-Ichi Teranishi, Kazuhide Makiyama iD, Hiroji Uemura, Hiroshi Miyamoto iD, Takashi Kawahara

Cancers · 06.11.2025 · 17 (21) · 3588

DOI: 10.3390/cancers17213588 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 06.11.2025. Verfasst von Sahoko Ninomiya und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama 232-0024, Japan. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Bladder cancer is associated with a high recurrence rate, and outcomes for muscle-invasive and metastatic disease remain poor. New targeted therapies, such as the FGFR inhibitor erdafitinib, have been introduced, but the progression from non-muscle-invasive to muscle-invasive disease remains a major clinical challenge.

Methods

In this study, we performed immunohistochemical staining for FGFR1-FGFR4 on surgical specimens from 192 cases of urothelial carcinoma. We also conducted various functional assays on human bladder cancer cell lines to assess protein/gene expression, cell proliferation, migration, invasion, and colony formation.

Results

FGFR2 and FGFR3 expressions were found to be significantly down-regulated in high-grade (0.014) and muscle-invasive (0.002) tumors, respectively. Functionally, the FGFR inhibitor erdafitinib suppressed cell proliferation and migration, and FGFR3 silencing also markedly reduced proliferation, migration, invasion, and colony formation in cancer cell lines.

Conclusions

The down-regulation of FGFR3 in muscle-invasive bladder cancer, coupled with the inhibitory effect of its inactivation on cell growth, suggests a significant role for FGFR3 in bladder cancer progression.

Schlagwörter

Stichwörter der Autor:innen

FGFRbladder cancererdafitinibmuscle-invasiveurothelial carcinoma

Autor:innen und Institutionen

  • Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama 232-0024, Japan.
  • Department of Urology, Yokohama City University School of Medicine, Yokohama 236-0004, Japan.
  • Departments of Pathology & Laboratory Medicine and Urology, University of Rochester Medical Center, Rochester, NY 14642, USA.

ORCID-Profile: Hisashi Hasumi, Akihito Hashizume, Kazuhide Makiyama, Hiroshi Miyamoto

Zitieren

APA

Ninomiya, S., Ishiguro, Y., Hasumi, H., Jikuya, R., Hashizume, A., Yamazaki, M., Teranishi, J. I., Makiyama, K., Uemura, H., Miyamoto, H., & Kawahara, T. (2025). The Role of FGFR3 in the Progression of Bladder Cancer. Cancers, 17(21), 3588. https://doi.org/10.3390/cancers17213588

Vancouver

Ninomiya S, Ishiguro Y, Hasumi H, Jikuya R, Hashizume A, Yamazaki M, et al. The Role of FGFR3 in the Progression of Bladder Cancer. Cancers. 2025;17(21):3588. doi:10.3390/cancers17213588

BibTeX
@article{Ninomiya2025,
  author = {Ninomiya, Sahoko and Ishiguro, Yukari and Hasumi, Hisashi and Jikuya, Ryosuke and Hashizume, Akihito and Yamazaki, Masanobu and Teranishi, Jun-Ichi and Makiyama, Kazuhide and Uemura, Hiroji and Miyamoto, Hiroshi and Kawahara, Takashi},
  title = {The Role of FGFR3 in the Progression of Bladder Cancer},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {21},
  pages = {3588},
  doi = {10.3390/cancers17213588}
}
Kostenlos starten →